Clinical trial
An Open-label, Single-center, Single-participant Study of an Experimental Antisense Oligonucleotide Treatment for a Patient With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)
NCT06816498 is registered in ClinicalTrials.gov with n-Lorem Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-center, Single-participant Study of an Experimental Antisense Oligonucleotide Treatment for a Patient With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)
- Lead sponsor
- n-Lorem Foundation
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- March 17, 2025
- Completion date
- March 31, 2027
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
autosomal dominant leukodystrophy